Kanamycin/ Aminopentamide/ Pectin/ Bismuth Subcarbonate/ Attapulgite

These indications are based on manufacturer information for both originator and generic products. For product specific registered indications, please refer to product specific manufacturer information

Registered South African indications:

• Gastroenteritis

Contraindications

• Hypersensitivity to the active ingredient or any of the excipients in this combination product
• Hypersensitivity to other aminoglycosides
• Glaucoma
• Myasthenia gravis
• Prostatic hypertrophy

Cautions

• Pregnancy
• Breastfeeding
• Renal impairment
• Hepatic impairment
• Elderly
• Infants and young children
• Prolonged use
• Coadministration with ototoxic, nephrotoxic or neuromuscular blocking agents
• Coadministration with antiemetics (See additional prescribing points)
• Coadministration with beta-lactam antibiotics (See additional prescribing points)
• Tartrazine sensitivity
• Aspirin sensitivity

Forms avail. in SA and covered in this monograph: tab, sus

Gastroenteritis - specific and non-specific

Kanamycin/ Aminopentamide/ Pectin/ Bismuth Subcarbonate/ Attapulgite
100/0.033/25/250/500 (mg)

• Oral (tab): 3 tab, 6hrly; Treatment duration: ≤3 days

In severe cases, the dose may be initially administered 4hrly

100/0.033/25/250/500 (mg/5ml)

• Oral (sus): 15ml, 4-6hrly; Treatment duration: ≤3 days

Shake the suspension thoroughly before administration of each dose

Paed. forms avail. in SA and covered in this monograph: sus

Gastroenteritis - specific and non-specific

Kanamycin/ Aminopentamide/ Pectin/ Bismuth Subcarbonate/ Attapulgite
100/0.033/25/250/500 (mg/5ml)

• Younger than 1 year: No information available
• Between 1-6 years: 5ml, 4-6hrly; Treatment duration: ≤3 days
• Between 6-12 years: 10ml, 4-6hrly; Treatment duration: ≤3 days
• Older than 12 years: See adult dosage

Shake the suspension thoroughly before administration of each dose 

Pregnancy

• Caution; no information available

Breastfeeding

• Caution; no information available

Renal Impairment

• Caution; no information available

Hepatic Impairment

• Caution; no information available

Elderly

• Caution; no information available

Drugs in Sport

• Permitted - No warnings

Central Nervous System Disorders

• Seizures
• Headache
• Paraesthesia
• Cerebral excitation
• Reversible encephalopathy

Gastrointestinal Disorders

• Dry mouth
• Black discolouration of faeces

Hepatobiliary Disorders

• Increased serum aminotransferase values
• Increased serum bilirubin concentrations

Genitourinary Disorders

• Reversible nephrotoxicity
• Acute renal failure

Endocrine and Metabolic Disorders

• Hypomagnesaemia
• Hypocalcaemia
• Hypokalaemia

Musculoskeletal Disorders

• Bone and joint disorders

Skin and Subcutaneous Tissue Disorders

• Purpura

Immune, Blood and Lymphatic System Disorders

• Hypersensitivity reactions
  - Cross-sensitivity
• Anaemia
• Overgrowth of kanamycin resistant organisms
• Superinfections

Sensory Disorders

• Irreversible ototoxicity
  - Auditory ototoxicity
• Visual disturbances
  - Dimmed vision

• Neuromuscular blocking agents
• Ototoxic agents
• Nephrotoxic agents

• Audiometry
• Renal function
• Electrolytes

Additional observations

• Hydration status

Coadministration with beta-lactam antibiotics

• Kanamycin should be administered separately when concomitant therapy with a beta-lactam antibiotic is required

Coadministration with antiemetics

• Antiemetics may mask ototoxic symptoms

Kanamycin/ Aminopentamide/ Pectin/ Bismuth Subcarbonate/ Attapulgite has antibiotic, adsorbent, protective and demulcent properties.

COMBINATION PREPARATIONS

Kanamycin/ Aminopentamide/ Pectin/ Bismuth Subcarbonate/ Attapulgite

Tablet 100mg/0.033mg/25mg/250mg/500mg

• Kantrexil (Opus) originator

Suspension (per 5ml) 100mg/0.033mg/25mg/250mg/500mg

• Kantrexil (Opus) originator